Autonomix Medical, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Autonomix Medical's CEO, Bradley Hauser, had his 45,000 stock options cancelled by mutual agreement, receiving three months of severance.
NASDAQ
Autonomix Medical Director Christopher Capelli cancelled 3,750 stock options without consideration, following a 1-for-20 reverse stock split.
NASDAQ
Autonomix Medical Director Walter Klemp's stock option for 8,773 shares was cancelled by mutual agreement, with no consideration received.
NASDAQ
Autonomix Medical Director Lori Bisson cancelled 65,542 stock options without receiving any consideration, following a 1-for-20 reverse stock split.
NASDAQ
Autonomix Medical's CFO, Trent N. Smith, cancelled stock options for 32,655 shares in exchange for three months of additional severance.
NASDAQ
David Andrew Robins, a director of Autonomix Medical, Inc., reported the acquisition of derivative securities, specifically warrants, on June 18, 2024.
NASDAQ
Director Lori Bisson acquired options to purchase 377,221 shares of Autonomix Medical stock on June 21, 2024.
NASDAQ
Director Walter Klemp acquired options to purchase 175,452 shares of Autonomix Medical stock on June 21, 2024.
NASDAQ
Autonomix Medical's CFO, Trent N. Smith, reported the acquisition of stock options in a recent SEC Form 4 filing.
NASDAQ
Autonomix Medical's CEO, Bradley Hauser, reports the acquisition of 900,000 options in the company, vesting over four years.
NASDAQ
BioStar Ventures III, L.P., a 10% owner of Autonomix Medical, Inc., acquired warrants to purchase 1,088,000 shares of common stock on June 18, 2024.